Abstract
In 2001, the Bridging Study Evaluation (BSE) review process based on the ICH E5 guideline was introduced in Taiwan. The purpose of BSE is to assess the impact of ethnic factors on a drug’s safety and efficacy and to determine whether pharmaceutical sponsors should conduct regional bridging studies in Taiwan. In this report, we provide the background and experience of BSE implementation in Taiwan and its influence on the global drug development process. Our BSE review process, allowing bridging studies to be waived, has successfully prevented conducting clinical trials with meaningless results. The trend of Investigational New Drug Application submission after New Drug Application (post-NDA) in other countries has also been shifted to the pre-NDA stage. The implementation of BSE in new regions has encouraged the pharmaceutical industry to consider the impact of ethnic factors in the early phase of clinical studies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacal Ther. 2008;84(3):287–293.
ICH Expert Working Group. Ethnic factors in the acceptability of foreign clinical data E5 (R1). ICH Harmonized Tripartite Guideline, current step 4 version, 1998.
Lin M, Chu CC, Chang SL, et al. The origin of Minnan and Hakka, the so-called “Taiwanese,” inferred by HLA study. Tissue Antigens. 2001;27:192–199.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Su, LL., Chern, HD., Lee, IL.R. et al. An Overview of Bridging Study Evaluation in Taiwan. Ther Innov Regul Sci 43, 371–376 (2009). https://doi.org/10.1177/009286150904300317
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150904300317